Study of the Immunological Efficacy of Using Subcutaneous Interleukin-2 (IL-2) in Antiretroviral Naive HIV-1-Infected Subjects With a CD4 Cell Count Above 300/mm3. ANRS 119 Trial INTERSTART

Trial Profile

Study of the Immunological Efficacy of Using Subcutaneous Interleukin-2 (IL-2) in Antiretroviral Naive HIV-1-Infected Subjects With a CD4 Cell Count Above 300/mm3. ANRS 119 Trial INTERSTART

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2009

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms INTERSTART
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Feb 2007 Status changed from in progress to completed
    • 04 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top